Free cholesterol transfer to high-density lipoprotein (HDL) upon triglyceride lipolysis underlies the U-shape relationship between HDL-cholesterol and cardiovascular disease

Abstract

Background

Low concentrations of high-density lipoprotein cholesterol (HDL-C) represent a well-established cardiovascular risk factor. Paradoxically, extremely high HDL-C levels are equally associated with elevated cardiovascular risk, resulting in the U-shape relationship of HDL-C with cardiovascular disease. Mechanisms underlying this association are presently unknown. We hypothesised that the capacity of high-density lipoprotein (HDL) to acquire free cholesterol upon triglyceride-rich lipoprotein (TGRL) lipolysis by lipoprotein lipase underlies the non-linear relationship between HDL-C and cardiovascular risk.

Methods

To assess our hypothesis, we developed a novel assay to evaluate the capacity of HDL to acquire free cholesterol (as fluorescent TopFluor® cholesterol) from TGRL upon in vitro lipolysis by lipoprotein lipase.

Results

When the assay was applied to several populations markedly differing in plasma HDL-C levels, transfer of free cholesterol was significantly decreased in low HDL-C patients with acute myocardial infarction (−45%) and type 2 diabetes (–25%), and in subjects with extremely high HDL-C of >2.59 mmol/L (>100 mg/dL) (−20%) versus healthy normolipidaemic controls. When these data were combined and plotted against HDL-C concentrations, an inverse U-shape relationship was observed. Consistent with these findings, animal studies revealed that the capacity of HDL to acquire cholesterol upon lipolysis was reduced in low HDL-C apolipoprotein A-I knock-out mice and was negatively correlated with aortic accumulation of [³H]-cholesterol after oral gavage, attesting this functional characteristic as a negative metric of postprandial atherosclerosis.

Conclusions

Free cholesterol transfer to HDL upon TGRL lipolysis may underlie the U-shape relationship between HDL-C and cardiovascular disease, linking HDL-C to triglyceride metabolism and atherosclerosis.

Keywords

Lipoprotein lipase atherosclerosis postprandial lipid metabolism apolipoproteins chylomicrons HDL function HDL metabolism LCAT lipoprotein metabolism CETP

Get full access to this article

View all access options for this article.

References

Kontush

Chapman

. High-density lipoproteins: Structure, metabolism, function and therapeutics, New York: Wiley & Sons, 2012, pp. 648–648.

Luscher

Landmesser

von Eckardstein

, et al. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res 2014; 114: 171–182.

Keene

Price

Shun-Shin

, et al. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: Meta-analysis of randomised controlled trials including 117,411 patients. BMJ 2014; 349: g4379–g4379.

Alter

Guo

, et al. High-density lipoprotein cholesterol and cause-specific mortality in individuals without previous cardiovascular conditions: The CANHEART Study. J Am Coll Cardiol 2016; 68: 2073–2083.

Hirata

Okamura

Sugiyama

, et al. The relationship between very high levels of serum high-density lipoprotein cholesterol and cause-specific mortality in a 20-year follow-up study of Japanese general population. J Atheroscler Thromb 2016; 23: 800–809.

Madsen

Varbo

Nordestgaard

. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: Two prospective cohort studies. Eur Heart J 2017; 38: 2478–2486.

Rader

Tall

. The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Nat Med 2012; 18: 1344–1346.

Bhatt

Rohatgi

. HDL Cholesterol efflux capacity: Cardiovascular risk factor and potential therapeutic target. Curr Atheroscler Rep 2016; 18: 2–2.

Rosenson

Brewer

Jr Davidson

, et al. Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport. Circulation 2012; 125: 1905–1919.

10.

Nordestgaard

Varbo

. Triglycerides and cardiovascular disease. Lancet 2014; 384: 626–635.

11.

Rosenson

Davidson

Hirsh

, et al. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J Am Coll Cardiol 2014; 64: 2525–2540.

12.

Chapman

Le Goff

Guerin

, et al. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 2010; 31: 149–164.

13.

Nikkila

Taskinen

Sane

. Plasma high-density lipoprotein concentration and subfraction distribution in relation to triglyceride metabolism. Am Heart J 1987; 113: 543–548.

14.

Magill

Rao

Miller

, et al. Relationships between the metabolism of high-density and very-low-density lipoproteins in man: Studies of apolipoprotein kinetics and adipose tissue lipoprotein lipase activity. Eur J Clin Invest 1982; 12: 113–120.

15.

Ros

. Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk. Atherosclerosis 2000; 151: 357–379.

16.

Schwartz

VandenBroek

Cooper

. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res 2004; 45: 1594–1607.

17.

Pownall

Ehnholm

. The unique role of apolipoprotein A-I in HDL remodeling and metabolism. Curr Opin Lipidol 2006; 17: 209–213.

18.

Huang

Silva

Jerome

, et al. Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol 2011; 18: 416–422.

19.

Bisgaier

Glickman

. Intestinal synthesis, secretion, and transport of lipoproteins. Annu Rev Physiol 1983; 45: 625–636.

20.

Kontush

de Faria

Chantepie

, et al. Antioxidative activity of HDL particle subspecies is impaired in hyperalphalipoproteinemia: Relevance of enzymatic and physicochemical properties. Arterioscler Thromb Vasc Biol 2004; 24: 526–533.

21.

Chung

Dashti

. Lipolytic remnants of human VLDL produced in vitro. Effect of HDL levels in the lipolysis mixtures on the apoCs to apoE ratio and metabolic properties of VLDL core remnants. J Lipid Res 2000; 41: 285–297.

22.

Rutledge

Mullick

Gardner

, et al. Direct visualization of lipid deposition and reverse lipid transport in a perfused artery – roles of VLDL and HDL. Circ Res 2000; 86: 768–773.

23.

Chung

Tallis

Yalamoori

, et al. Liposome-like particles isolated from human atherosclerotic plaques are structurally and compositionally similar to surface remnants of triglyceride-rich lipoproteins. Arterioscler Thromb 1994; 14: 622–635.

24.

Schaefer

Wetzel

Bengtsson

, et al. Transfer of human lymph chylomicron constituents to other lipoprotein density fractions during in vitro lipolysis. J Lipid Res 1982; 23: 1259–1273.

25.

Sakurai

Vaisman

, et al. Development of a novel fluorescent activity assay for lecithin:cholesterol acyltransferase. Ann Clin Biochem 2018; 55: 414–421.

26.

Bisgaier

Minton

Essenburg

, et al. Use of fluorescent cholesteryl ester microemulsions in cholesteryl ester transfer protein assays. J Lipid Res 1993; 34: 1625–1634.

27.

Kosek

Durbin

Jonas

. Binding affinity and reactivity of lecithin cholesterol acyltransferase with native lipoproteins. Biochem Biophys Res Commun 1999; 258: 548–551.

28.

Paromov

Morton

. Lipid transfer inhibitor protein defines the participation of high density lipoprotein subfractions in lipid transfer reactions mediated by cholesterol ester transfer protein (CETP). J Biol Chem 2003; 278: 40859–40866.

29.

Vaisar

Pennathur

Green

, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117: 746–756.

30.

Asztalos

Horvath

Kajinami

, et al. Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. J Lipid Res 2004; 45: 448–455.

31.

Camont

Lhomme

Rached

, et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: Relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol 2013; 33: 2715–2723.

32.

Allard-Ratick MP, Kindya BR, Khambhati J, et al. HDL: Fact, fiction, or function? HDL cholesterol and cardiovascular risk. Eur J Prev Cardiol. Epub ahead of print 13 May 2019. DOI: 10.1177/2047487319848214.

33.

Richart

Heywood

Siebel

, et al. High-density lipoprotein and cardiac glucose metabolism: Implications for management of acute coronary syndromes. Eur J Prev Cardiol 2018; 25: 273–275.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.33 MB